## **Core Concept**
The question tests knowledge of pharmacological agents that affect muscle contraction, specifically those that target the myosin component of the actomyosin complex. Myosin activators are drugs that increase the activity of myosin, leading to enhanced muscle contraction. These are of interest in treating conditions like heart failure.

## **Why the Correct Answer is Right**
Omecamtiv mecarbil (**Option D**) is a selective cardiac myosin activator. It works by increasing the duration of myosin binding to actin, thereby enhancing cardiac contractility without significantly increasing oxygen demand. This mechanism is beneficial in the treatment of systolic heart failure, where the heart's ability to contract is impaired.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not correspond to a known selective myosin activator.
- **Option B:** This option is incorrect as it does not represent a recognized myosin activator.
- **Option C:** This option is incorrect because it is not identified as a selective myosin activator.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that omecamtiv mecarbil is being explored for its potential in treating heart failure with reduced ejection fraction (HFrEF). It represents a novel approach to enhancing cardiac contractility by directly targeting the myosin motor protein.

## **Correct Answer:** D. Omecamtiv mecarbil.